Metastatic hormone-naïve prostate cancer: a distinct biological entity

Abstract

Models experimentals; Metàstasi; Càncer de pròstata

Modelos experimentales; Metástasis; Cáncer de próstata

Experimental models; Metastasis; Prostate cancer

Metastatic hormone-naïve prostate cancer (mHNPC) is often the initial form of presentation for metastatic prostate cancer and encompasses a heterogeneous patient population with high inter-patient heterogeneity in prognosis and response to therapy. A more precise treatment of mHNPC, guided by evidence-based biomarkers, remains an unmet medical need. In addition, the limited number of representative laboratory models of mHNPC hampers the translation of basic research into clinical applications. We provide a comprehensive overview of the clinical and biological features that characterize mHNPC, highlight molecular data that could explain the unique prognostic characteristics of mHNPC, and identify key open questions.

We are thankful to Kathrin Keim for support with English editing. The work of A.C. is supported by the Basque Department of Industry, Tourism, and Trade (Elkartek), the BBVA Foundation (Becas Leonardo), the Ministerio de Ciencia e Innovación (MICINN; PID2022-141553OB-I0 ERDF (European Regional Development Fund)/EU]; the Fundación CRIS Contra el Cáncer ( PR_EX_2021-22 ), Severo Ochoa Excellence Accreditation ( CEX2021-001136-S ), the European Training Networks Project ( H2020-MSCA-ITN-308 2016 721532), the Spanish Association Against Cancer (AECC; GCTRA18006CARR ), the Fundación Jesús Serra, the iDIFFER Network of Excellence ( RED2022-134792-T ), the AstraZeneca Award for young scientists ( 2023 call) and the European Research Council (consolidator grant 819242 ). CIBERONC was cofunded with FEDER funds and funded by the Instituto de Salud Carlos III (ISCIII). J.M. is supported by a CRIS Talent Award ( TALENT20-10 ) and a Department of Defense Congressionally Directed Medical Research Program (CDMPR) Physician-Science Award ( PC220307 ). VHIO authors would like to acknowledge the Spanish State Agency for Research (Agencia Estatal de Investigación) for financial support as a Center of Excellence Severo Ochoa ( CEX2020-001024-S/AEI/10.13039/501100011033 ), the Cellex Foundation for providing research facilities and equipment, and the Foundation for Oncological Studies and Research (FERO) and the Centres de Recerca de Catalunya (CERCA) Programme from Generalitat de Catalunya for their support.